Overview

Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase IV trial to study the effectiveness of amifostine in treating patients with cancer who have neurological changes caused by chemotherapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rush North Shore Medical Center
Treatments:
Amifostine
Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically proven cancer No brain or other
CNS metastases (including prior treated metastases)

PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy: Not
specified Hematopoietic: Not specified Hepatic: No grade 3 or greater hepatic dysfunction
Renal: No hypercalcemia Cardiovascular: No uncontrolled hypotension Other: Not pregnant or
nursing Effective contraceptive method must be used by fertile patients No psychosis No
severe concurrent illness other than neoplasia No epileptic seizures during the previous
year, migraines, gastrointestinal obstructions, or other causes of vomiting No prior or
concurrent amifostine contraindications No prior known contraindications or sensitivity to
dexamethasone, granisetron, ondansetron, prochlorperazine, diphenhydramine, cimetidine, or
magnesium

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: No prior estrogen within 24 hours of amifostine therapy Radiotherapy:
Not specified Surgery: Not specified Other: No prior alcohol, disulphiram, tetracycline, or
erythromycin within 24 hours of amifostine therapy No prior antiemetics such as
benzodiazepines, antipsychotics, anticonvulsants, or antihistamines within 24 hours of
amifostine therapy